Find a Clinical Trial
The clinical trials at Gundersen offer the same cutting-edge treatments as those at other top medical research hospitals – and often much sooner than they’re available to everyone.
Showing 10 of 87 trials
NCI-2022-07006
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Adult (18-64)
Older adult (65+)
NCI-2021-06042
Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative
Adult (18-64)
Older adult (65+)
NCI-2022-01540
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Adult (18-64)
Older adult (65+)
NCI-2024-07049
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Adult (18-64)
Older adult (65+)
NCI-2022-10845
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Child (birth - 17)
Adult (18-64)
V712-308
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
Child (birth - 17)
GS-US-600-6165
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Adult (18-64)
Older adult (65+)
NCI-2022-06842
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Child (birth - 17)
Adult (18-64)
Older adult (65+)
A012103
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Adult (18-64)
Older adult (65+)
NCI-2024-05588
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Adult (18-64)
Older adult (65+)